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According to the guidelines of the European Stroke Organization (ESO) and the American
Stroke Association (ASA), acute stroke patients should be managed at stroke units that
include well organized pre- and in-hospital care. In ischemic stroke the restoration of blood
ﬂow has to occur within a limited time window that is accomplished by ﬁbrinolytic therapy.
Newer generation thrombolytic agents (alteplase, pro-urokinase, reteplase, tenecteplase,
desmoteplase) have shorter half-life and are more ﬁbrin-speciﬁc. Only alteplase has Food
and Drug Administration (FDA) approval for the treatment of acute stroke (1996). The
National Institute of Neurological Disorders and Stroke (NINDS) trial proved that alteplase
was effective in all subtypes of ischemic strokes within the ﬁrst 3 h. In the European coop-
erative acute stroke study III trial, intravenous (IV) alteplase therapy was found to be safe
and effective (with some restrictions) if applied within the ﬁrst 3–4.5 h. In middle cere-
bral artery (MCA) occlusion additional transcranial Doppler insonication may improve the
breakdown of the blood clot. According to the ESO and ASA guidelines, intra-arterial (IA)
thrombolysis is an option for recanalization within 6 h of MCA occlusion. Further trials on
the IA therapy are needed, as previous studies have involved relatively small number of
patients (compared to IV trials) and the optimal IA dose of alteplase has not been deter-
mined (20–30mg is used most commonly in 2 h). Patients undergoing combined (IV+ IA)
thrombolysis had signiﬁcantly better outcome than the placebo group or the IV therapy
alone in the NINDS trial (Interventional Management of Stroke trials). If thrombolysis fails
or it is contraindicated, mechanical devices [e.g., mechanical embolus removal in cerebral
ischemia (MERCI)- approved in 2004] might be used to remove the occluding clot. Stenting
can also be an option in case of acute internal carotid artery occlusion in the future. An
intra-aortic balloon was used to increase the collateral blood ﬂow in the Safety and Efﬁcacy
of NeuroFlo™ Technology in Ischemic Stroke trial (results are under evaluation). Currently,
there is no approved effective neuroprotective drug.
Keywords: intravenous thrombolysis, intra-arterial thrombolysis, acute stroke, mechanism of recanalization,
thrombectomy, alteplase, stroke unit, therapeutic time window
INTRODUCTION
Stroke is the third most common cause of death and it is the most
commonly disabling disease. The care of stroke patients is chal-
lenging, because there is no easy method to rapidly establish the
diagnosis at the patient’s home like in some of the acute myocar-
dial infarction cases (e.g., EEG). It is also impossible to distinguish
hemorrhagic strokes from ischemic strokes based solely on clinical
symptoms; for that a brain CT must be performed. The time win-
dow for therapy is short and none of the neuroprotective agents
have been proven to be effective yet.
The effective treatment of ischemic strokes today relies on
rapid mechanical endovascular or pharmacological revascular-
ization of the affected areas. The 1995 National Institute of
Neurological Disorders and Stroke (NINDS) trial represented a
breakthrough, as it was the ﬁrst to prove in a randomized study
that ﬁbrin-speciﬁc agents could lead to both revascularization and
clinical improvement in all subtypes of ischemic stroke, advancing
stroke therapy beyond the previously used non-ﬁbrin-speciﬁc
drugs (The National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995). tissue type-plasminogen
activator (t-PA) was approved by the Food and Drug Administra-
tion (FDA) in 1996 and iswidely used for the treatment of ischemic
strokes.
Because pharmacological thrombolysis is not 100% success-
ful, mechanical thrombectomy has also attracted attention in the
last few years. These techniques use intra-arterial (IA) devices to
remove the clot or sclerotic debris from the occluded artery, which
remain insoluble following thrombolysis.
In this review we discuss the:
• importance of early revascularization in acute ischemic stroke,
• experience with ﬁbrinolytics,
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• methods of intravenous (IV), IA, and combined (IV+ IA)
thrombolysis,
• recent results with mechanical revascularization (recanaliza-
tion) techniques.
TIME IS OF ESSENCE: THE IMPORTANCE OF EARLY
REVASCULARIZATION (RECANALIZATION)
The size of the ischemic lesion is proportional to the caliber of the
occluded artery, and to the duration of the occlusion, and will only
be reduced by the blood ﬂow available through the collaterals. A
general rule (with many exceptions) is that distal occlusions (e.g.,
middle or anterior cerebral artery) have a higher risk for cerebral
infarction than proximal ones [e.g., internal carotid artery (ICA)]
because the latter has more collateral blood ﬂow available to com-
pensate. A sudden arterial occlusion triggers the development of
the ischemic cascade.
Decreased blood perfusion of the brain results in oxygen and
glucose deﬁcit. The consequences are extracellular calcium and
sodium inﬂux into the intracellular space and potassium efﬂux.
Calcium inﬂux activates lipase enzymes and the release of exci-
tatory amino acids. Neurotransmitters and free radicals are pro-
duced followed by cytokine release and several additional catabolic
mechanisms are induced. Intracellular ion changes occur within a
short time; this phenomenon can be used for detecting the abnor-
mal cellular water movement within minutes of the symptom
onset of ischemic strokes using diffusion MRI (Kuroiwa et al.,
2007).
Therapeutic strategies were signiﬁcantly altered by the devel-
opment of the theory of the “ischemic penumbra” (Figure 1).
This hypothesis does not consider the ischemic region a homo-
geneous dead tissue with sharp edges separated from the intact
tissue (Astrup et al., 1981; Csiba et al., 1983, 1985). Rather, only
the ischemic core, where the blood ﬂow is below the critical value
of 7.7–14ml/100 g/min, is considered to be irreversibly damaged.
The region surrounding this area has functional deﬁcit (“elec-
tric silence”) with otherwise preserved integrity of the tissues
(ischemic penumbra) and is an area at risk. This is the area we
aim to salvage during stroke interventions. The success of our
rescue efforts will depend on the duration of the ischemia, on the
degree of revascularization and on additional factors such as blood
pressure, serum glucose, etc. (Segura et al., 2008).
FIGURE 1 | Structure of the ischemic penumbra.
Both animal and human studies proved that the size of the
penumbra (the salvageable area at risk) is shrinking as time goes
on while the area of permanent damage is expanding. Therefore
recanalization of the occluded artery should happen within a few
hours after the onset of the focal ischemic stroke, otherwise 120
million neurons, 830 billion synapses, and 714 km axons die each
hour (Saver, 2006).
FIBRINOLYTIC DRUGS
Agents available for IV or IA thrombolysis are: streptokinase,
urokinase, alteplase, pro-urokinase, reteplase, tenecteplase, and
desmoteplase.
FIRST GENERATION FIBRINOLYTICS (STREPTOKINASE, UROKINASE)
These agents only have historical importance (Cornu et al., 2001).
They are not ﬁbrin-speciﬁc. They induce ﬁbrinolysis but they
also decrease the level of ﬁbrinogen, coagulation factors, and von
Willebrand factor in the blood. Streptokinase, an enzyme secreted
by several species of streptococci, can activate human plasmino-
gen. Since it has immunological side effects (allergic reactions)
and increases the risk of intracranial hemorrhage, it is no longer
used for thrombolysis. Urokinase was also tested for both IV and
IA thrombolysis, but it has not signiﬁcantly improved clinical
outcomes (Murray et al., 2010).
SECOND GENERATION FIBRINOLYTICS (ALTEPLASE, PRO-UROKINASE)
Alteplase and pro-urokinase are more ﬁbrin-speciﬁc and have
no immunological side effects compared to the previous group.
Alteplase (rt-PA) is the only FDA approved ﬁbrinolytic drug in
acute ischemic stroke. It has a short half-life (4–6min) but unfor-
tunately it also has some neurotoxic side effects by activating a
metalloproteinase. This enzyme modulates the blood–brain bar-
rier, which results in an increased risk for intracerebral bleeding
and brain edema (Micieli et al., 2009).
Pro-urokinase (half-life 7min) has been also tested in clin-
ical trials, but unfortunately despite the good clinical results it
has not received FDA approval yet. The prolyse in acute cerebral
thromboembolism II (PROACT II) trial (Furlan and Abou-Chebl,
2002) compared the efﬁcacy of IA pro-urokinase treatment with
IV heparin in middle cerebral artery (MCA) occlusion. Recanal-
ization rate was 66% in the pro-urokinase, and 18% in the heparin
group, while 40% of the cases in the pro-urokinase and 25% in the
heparin group had good clinical outcome (less than two on the
modiﬁed Rankin Scale; Furlan and Abou-Chebl, 2002) (Table 3).
THIRD GENERATION FIBRINOLYTICS (RETEPLASE, TENECTEPLASE)
Since rt-PA might damage the blood–brain barrier, there are fur-
ther efforts for developing ﬁbrinolytics with fewer side effects.
Reteplase and tenecteplase are modiﬁed forms of alteplase with
longer half-life and have only been applied in trials yet.
The ﬁrst prospective human clinical trial evaluated the safety
and efﬁcacy of IA reteplase treatment in 16 patients with ischemic
stroke who were poor candidates for IV alteplase therapy. Near
complete or complete recanalization was observed after treatment
in 88% of the patients (Qureshi et al., 2002).
In a preliminary safety trial different doses of IA reteplase
were combined with IV administered abciximab (platelet aggre-
gation inhibitor, glycoprotein IIb/IIIa). The patients were treated
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between 3 and 6 h following the onset of their symptoms. There
was one symptomatic intracerebral hemorrhage and 13 success-
ful recanalization among the 20 patients treated. Thirteen patients
demonstrated early neurological improvement and favorable out-
come was observed in six patients after 1month (Qureshi et al.,
2006).
Tenecteplase has a longer half-life (17min) and is more
ﬁbrin-speciﬁc than alteplase.
In another study, low-dose tenecteplase (0.1mg/kg)was applied
IV in a small group of patients (N = 15) between 3 and 6 h after the
onset of cerebral arterial occlusion; patients had a perfusion deﬁcit
of at least 20% larger than the infarct core (perfusion/angiographic
CT/MR). Their results were compared to the outcome of 35
patients treated within the ﬁrst 3 h with rt-PA following the stan-
dard selection criteria (Parsons et al., 2009). Tenecteplase showed
signiﬁcantly higher recanalization rate compared to alteplase (74
vs. 44%). Despite the fact that the treatment was started later and
the symptomsweremore severe in the tenecteplase-group,patients
showed better improvement at 24 h after the therapy than those
patients who were treated with alteplase. Four of the alteplase
treated patients and none of the tenecteplase treated patients had
parenchymal hematoma at 24 h.
Haley et al. (2005) found the dose of 0.1–0.4mg/kg of
tenecteplase safe to be used in acute stroke. Eighty-eight patients
were treated within the ﬁrst 3 h. The lower doses of tenecteplase
(0.1, 0.2, or 0.4mg/kg) caused only asymptomatic intracerebral
bleeding (in 8–32% of the cases in the separated subgroups),
while the higher doses (0.5mg/kg) caused both asymptomatic
and symptomatic intracerebral bleeding (in 13 and 23% of the
13 treated patients). According to the modiﬁed Rankin scale
tenecteplase showed similar results as alteplase at the 3-month
follow-up period.
FOURTH GENERATION OF FIBRINOLYTICS (DESMOTEPLASE)
The fourth generation ﬁbrinolytics are produced by genetic
methods.
Desmoteplase (more ﬁbrin-speciﬁc, has no neurotoxicity) has
been tested in the desmoteplase in acute stroke (DIAS) 2–4 tri-
als (Paciaroni et al., 2009). DIAS was a randomized, placebo-
controlled trial with a 3 to 9-h time window (Hacke et al., 2005)
for treatment eligibility. Patients with moderate symptoms and
diffusion/perfusion mismatch on the MRI were randomized into
placebo and ﬁx dose of IV desmoteplase groups. A symptomatic
intracranial hemorrhage was observed in 30.8% of the patients in
the high-dose (37.5 or 50mg) and 23.5% of the patients in the
low-dose (25mg) group in the ﬁrst part of the trial. Subsequently,
the study was continued with considerably lower dosages (90 and
125μg/kg). There the occurrence of symptomatic intracranial
bleeding in the desmoteplase group was found to be only 2.2%.
However, the results of DIAS-2 trial could not support these favor-
able ﬁndings. In the DIAS-2 trial almost 200 patients were ran-
domized into groups treated with different doses of desmoteplase.
Inclusion criteria of thepatientswasdiffusion/perfusionmismatch
on MR/CT. Treatment was initiated between 3 and 9 h after the
onset of stroke. Unfortunately, neither the 90 nor the 125-μg/kg
dosages were found to be effective. Additionally, mortality was
higher in the group treated with 125μg/kg compared to both the
placebo-treated group and the group which received the 90-μg/kg
dose (Liebeskind, 2009). The rate of bleeding was 4.5% in the
higher dose and 3.5% in the lower dose treatment group and 0%
in the placebo group. The DIAS-3 and -4 trials are still ongoing.
They are comparing the effect of placebo with IV desmoteplase
treatment (90μg/kg dose) given between the ﬁrst 3–9 h after acute
stroke.
In conclusion: at present the evidence is strongest for alteplase
to be a clinically effective ﬁbrinolytic in acute stroke, but research
is still ongoing to ﬁnd a more ﬁbrin-speciﬁc agent with shorter
half-life and less neurotoxic side effects.
INTRAVENOUS FIBRINOLYSIS IN THE CLINICAL PRACTICE
The NINDS trial produced a real breakthrough in ﬁbrinolytic
therapy. It proved the efﬁcacy of rt-PA (alteplase) therapy in all
subtypes of ischemic stroke. It also proved that the beneﬁts of
thrombolysis (rt-PA) extend beyond 1 year after the treatment
(Kwiatkowski et al., 1999).
However, the 3-h time window for treatment has proven to be
too short in clinical practice. Therefore, several subsequent stud-
ies have investigated the feasibility of a wider, but still safe time
window.
The results of European cooperative acute stroke study
(ECASS-III), a placebo-controlled trial, using IV rt-PA in the 3 to
4.5-h time window, were published in 2008 (Saver et al., 2009).
This placebo-controlled trial proved the safety of IV thromboly-
sis within the ﬁrst 3–4.5 h following ischemic stroke with patient
listed below excluded from the trial.
• Younger than 18 or older than 80 years
• Severe neurological symptoms National Institute of Health
Stroke Scale (NIHSS)>25
• Taking anticoagulant (irrespectively of hemostatic parameters)
• History of diabetes mellitus and a previous stroke
In this study excellent clinical outcomes (0 or 1 point on the mod-
iﬁed Rankin Scale) were more frequent in the rt-PA treated group
than in the placebo group (52 vs. 45%, p = 0.04) 3months after
treatment. The mortality in the rt-PA treated group was not sig-
niﬁcantly different from that of placebo group (17% in the treated
group a 21% in the placebo group). While, symptomatic intracra-
nial bleedings were more frequent in the t-PA group (2.4 vs. 0.2%,
p = 0.001).
Before initiating IV thrombolysis, the cost-beneﬁt ratiomust be
calculated. The inclusion and exclusion criteria must be followed
strictly (Table 2). When doing so, one has to bear in mind that 32
patients out of 100 thrombolysed will likely to show improvement
and only three is likely to have harm (Saver, 2004). Follow-up
studies also support the fact: the earlier the thrombolysis is per-
formed the better clinical improvement can be achieved. One of
two patients will likely become symptom-free or have minimal
residual symptoms if treated with IV thrombolysis (Marler et al.,
2000; Saver et al., 2010) within the ﬁrst hour following a stroke.
This ratio drops to 1 out of 4 if treated between 60 and 90min after
the onset of stroke, and 1 out of 9 between the ﬁrst 90–180min,
further diminishing to 1 out of 21 patients if treatment is delayed
to 180–270min. Time lost is brain lost!
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Table 1 | Recommendations for the specific treatment of acute
ischemic stroke.
Intravenous rt-PA (0.9mg/kg body weight, max. 90mg) is recommended
within the ﬁrst 3 h (in selected cases also between the ﬁrst 3 and 4.5 h)
of the ischemic stroke. 10% of the calculated dose is given as an iv. bolus
injection, 90% is given under 60 minutes as an iv. infusion.
Lower blood pressure under 185/110mmHg before initiating thrombolysis.
Intravenous rt-PA may be used in patients with seizures at stroke onset, if
the neurological deﬁcit is related to acute cerebral ischemia.
Age: intravenous rt-PA may also be administered in selected patients under
18 years and over 80 years of age.
Intra-arterial treatment of acute MCA occlusion within a 6-h time window
with rt-PA is an option.
Acute basilar occlusion: intra-arterial thrombolysis is recommended for
selected patients and intravenous thrombolysis is acceptable even after 3 h.
If thrombolytic therapy is given antithrombotic therapy should not be ini-
tiated within 24 h, but Aspirin (160–325mg loading dose) should be given
within the ﬁrst 48 h of ischemic stroke. The use of other antiplatelet drug is
not accepted in acute stroke.
Early administration of unfractionated heparin, lowmolecular weight heparin
is not recommended.
The European Stroke Organization: guidelines for management of ischemic stroke
and transient ischemic attack 2008.
Therefore medical systems must have a “fast lane” for patients
arriving to the hospital for thrombolysis. The optimal time win-
dow for completing diagnostic workup and initiating IV treatment
should not exceed 60min.
The recommended dose of rt-PA used IV is 0.9mg/kg. A max-
imum total dose of 90mg can be given. Ten percent of this must
be injected in a bolus. The rest should be administered within the
next hour (Table 1). The patient cannot receive antiplatelet or anti-
coagulant drugs within the ﬁrst 24 h if thrombolysis was applied.
One day after thrombolysis a cranial CT must be performed to
detect intracranial bleed.
ULTRASOUND-ENHANCED INTRAVENOUS THROMBOLYSIS
Alexandrov (Molina et al., 2004) used a commercially available,
2MHz transcranial Doppler ultrasound (TCD) to facilitate the
effect of rt-PA and to improve revascularization (recanalization)
rate during IV thrombolysis for arterial occlusion. Ultrasound
(US) enhances the interaction between rt-PA and ﬁbrin. The
vibration and the thermal effects improve the breakdown of the
clot. The 2-MHz US penetrates through the cranial bone, visu-
alizes the intracranial arteries and measures the direction and
speed of the blood ﬂow in the vessels. According to his obser-
vations (Alexandrov, 2010a), complete or partial recanalization
occurred in 83% of the US-enhanced thrombolysis cases whereas
the rate of recanalization was 50% when IV thrombolysis was
used alone. Symptomatic intracranial bleeding occurred in 3.8%
of both groups. Neurological outcome at 3months was also better
(51%) in the US-enhanced group compared to the group with IV
thrombolysis alone (37%).
It is almost a futuristic idea to enhance thrombolysis with
both US sonication and micro bubbles. Five micrometer size
micro bubbles can be given intraveniously. The microbubbles are
destroyed by the US applied through the temporal bone window.
This mechanical interaction can further enhance thrombolysis.
In a recent trial 111 patients with acute MCA occlusion were
treated with some combination of these interventions. Thirty-
eight patients were treated with rt-PA plus continuous 2 h long
TCD monitoring plus galactose-based micro bubbles. The rest
of the patients received rt-PA plus continuous 2 h TCD–US
insonation (N = 37) or t-PA plus placebo monitoring (N = 36).
Successful revascularizationwas seen in 55%of those patients who
received all three interventions (including micro bubbles). The
revascularization rate was 41% for those who received rt-PA and
additional TCD sonication therapy, and 24% for those who under-
went rt-PA therapy alone. More than 56% of the patients receiving
combined treatment, including micro bubbles, showed excel-
lent clinical improvement (improved >4 points on NIHSS) by
1 day after treatment vs. those receiving rt-PA +TCD–US therapy
(41%) and conventional thrombolysis alone (31%; Molina et al.,
2006). Despite the promising results, sono-thrombolysis is still
considered to be an experimental method. The efﬁcacy depends
on the presence of the bone window (10–15% of patients, espe-
cially women cannot be effectively sonicated), and the technique
is also operator dependent.
INTRAVENOUS THROMBOLYSIS OUTSIDE OF THE TIME
WINDOW
The new MRI techniques (diffusion MRI and the combination of
MRI and CT) may help in the selection of patients who might
beneﬁt from thrombolysis even after 3 or 4.5 h after the onset
of stroke. (Note: if the diffusion deﬁcit is small and the perfu-
sion deﬁcit is large, a diffusion–perfusion mismatch exists and it
might be still worth initiating thrombolysis). Based on such strat-
egy, 72 patients were treated between 3 and 6 h after the onset of
stroke with IV rt-PA in the diffusion-weighted imaging evaluation
for understanding stroke evolution (DEFUSE) trial (Olivot et al.,
2009). Those patients who had a diffusion–perfusion mismatch
beneﬁted from the treatment. Half of the 72 patients enrolled
did not have a diffusion–perfusion mismatch and those did not
beneﬁt from the thrombolysis. It was also found, that permeabil-
ity changes detected on MRI can also forecast the appearance of
hemorrhagic complications after rt-PA treatment (Kakuda et al.,
2008).
Another trial echoplanar imaging thrombolysis evaluation trial
(EPITHET), also used perfusion and diffusion MRI to enroll
patients for rt-PA treatment 3–6 h after stroke. The IV rt-PA
decreased the size of irreversibly damaged areas and improved
clinical outcome of those patients who had a diffusion–perfusion
mismatch on the MRI before the intervention (Davis et al., 2008).
The beneﬁt of extending the period of eligibility for throm-
bolysis to 9 h following an acute stroke is being evaluated by the
ongoing extending the time for thrombolysis in emergency neu-
rological deﬁcit (EXTEND)1 clinical trial, using modern imaging
techniques (diffusion, perfusion MRI, perfusion CT; Wintermark
et al., 2008).
1www.strokecenter.org/trials/TrialDetail.aspx?tid(1059
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Table 2 | Guidelines for the early management of adults with ischemic stroke (AHA/ASA Guideline).
Inclusion criteria Exclusion criteria
It is ischemic stroke causing the symptoms Symptoms are clearing spontaneously
Patients with major deﬁcits should be treated with caution Neurological signs are minor and isolated
Thrombolysis may be used in patients with seizures at the time of
presentation when evidence suggests that residual deﬁcits are due to
ischemia rather than the postictal state
Patient had a seizure and has most likely a postictal residual
neurological impairments
Thrombolysis can be initiated within the time window Head trauma, stroke, or myocardial infarction in the previous 3months
Patients on anticoagulant therapy with the INR ≤1.7 Gastrointestinal or urinary tract hemorrhage in previous 21 days
APTI is in the normal range Major surgery in the previous 14 days
Arterial puncture at a non-compressible site in the previous 7 days
History of previous intracranial hemorrhage
Uncontrollable blood pressure over 185/110mmHg
Evidence of active bleeding or acute trauma (fracture)
Patients on anticoagulant therapy with the INR >1.7
Patient received Heparin in the last 48 h
APTI: over the normal range
Platelet count <100G/L
Serum glucose level <2.7mmol/L (50mg/dl)
Symptoms are suggestive of subarachnoid hemorrhage
CT shows a hypodensity >1/3 of the cerebral hemisphere
Table 3 | Modified Rankin Scale
(www.strokecenter.org/trials/scales/rankin).
Score Description
0 No symptoms at all
1 No signiﬁcant disability despite symptoms; able to carry out all
usual duties and activities
2 Slight disability; unable to carry out all previous activities, but able
to look after own affairs without assistance
3 Moderate disability; requiring some help, but able to walk without
assistance
4 Moderately severe disability; unable to walk without assistance
and unable to attend to own bodily needs without assistance
5 Severe disability; bedridden, incontinent and requiring constant
nursing care and attention
6 Death
INTRA-ARTERIAL THROMBOLYSIS
The following are the theoretical advantages of IA thrombolysis in
acute ischemic stroke:
• Fibrinolytic agent can be directly injected into the thrombus
• Revascularization is detected immediately
• Lower dose can be given than in case of IV intervention
• The risk of hemorrhage is lower
The Disadvantages of IA thrombolysis:
• More time is needed for the preparations of the procedure
• Collaboration of interventional radiologists is needed
• Higher costs
• Possibility of arterial injuries
Despite the fact that the IA thrombolysis with rt-PA can be an
option for revascularization according to the European Stroke
Organization (ESO) 20082, and American Heart and Stroke Asso-
ciation (Adams et al., 2007) guidelines, further investigations are
recommend to deﬁne the appropriate role for this intervention.
This is because the recent studies included relatively small num-
ber of patients (compared with IV trials) and the optimal dose of
IA therapy has not been determined yet (most common dose IA
20–30mg in 2 h). Therefore further trials comparing the efﬁcacy
and safety of IV and IA thrombolysis are needed.
A meta-analysis (27 trials, 1117 patients) claimed that the IA
thrombolysis increased mortality rates and was associated with
worse functional outcome in minor strokes. Furthermore, this
meta-analysis suggests that the aggressive IA therapy in mild
strokes might result in worse outcomes than the natural course
of the disease (Wardlaw et al., 2009).
Recent trials on IA thrombolysis are the following:
In the PROACT I trial (randomized, placebo-controlled) 40
acute stroke patients with MCA occlusion were treated within
the ﬁrst 6 h of acute stroke with 6mg pro-urokinase (IA). All
patients received IV heparin as well. Recanalization was successful
in 57% of the patients treated with pro-urokinase and in 14% of
the patients treated with placebo (p = 0.017). Bleeding or clinical
decline occurred in 15% of the pro-urokinase and in 7% of the
placebo-treated patients (del Zoppo et al., 1998).
The subsequent PROACT II, a multicenter, randomized trial,
trial examined the effect of IA recombinant pro-urokinase on
MCA revascularization with treatment applied within the ﬁrst
6 h of stroke (Furlan et al., 1999). There were 180 patients who
received heparin or heparin +9mg IA pro-urokinase (slow IA
2www.eso-stroke.org/pdf/ESO%20Guidelines_update_Jan_2009.pdf
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infusion under 2 h; max. dose was given in each case regardless
of early recanalization). This study showed a 66% recanalization
rate in the pro-urokinase and 18% in the control group. The
non-disabling (0–2 point on the modiﬁed Rankin Scale) 3-month
functional outcome was signiﬁcantly better if pro-urokinase was
used compared to placebo (improvement: 40 vs. 25%, p = 0.04).
Intracerebral hemorrhage with neurological deterioration within
24 h occurred in 10.9% of the pro-urokinase group and 3.1%
of the controls. Death rates were similar in both groups. This
trial proved the efﬁcacy of pro-urokinase used within the ﬁrst
6 h of acute stroke in case of MCA occlusion. The results were
compared to the results of the NINDS trial. The 3-month out-
come was better than in the placebo-arm of the NINDS trial.
The 3-month mortality rates were lower in the PROACT II trial
(16%) compared to the placebo (24%) and the rt-PA treated
(21%) group of the NINDS trial (The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995).
Another IA urokinase (given in 120,000 IU boluses, total dose
of 600,000 IU within the ﬁrst 6 h of acute stroke) trial the so-
called MCA-embolism local ﬁbrinolytic intervention trial (MELT)
was performed in Japan. Partial or complete recanalization was
achieved in 74% of the subjects treated with urokinase. Favor-
able 3month outcomes, both non-disabling (0–2 points on the
modiﬁed Rankin Scale) and excellent (0–1 point on the modiﬁed
Rankin Scale), were more common in the urokinase group com-
pared to the control group (49.1 vs. 38.6% and 42.1 vs. 22.8%,
p = 0.045). Three-month mortality rates (5.3% in the urokinase
and 3.5% in the control group, p = 1.00) and the rate of symp-
tomatic intracerebral bleedings (9% in the urokinase and 2% in
the control group, p = 0.206) did not differ signiﬁcantly from the
control group. Since rt-PA was just approved in Japan during that
period, the MELT trial was stopped after the enrollment of 114
patients (Ogawa et al., 2007).
A recent meta-analysis (PROACT, PROACT II, and MELT)
showed that IA thrombolysis resulted in better 3-month clini-
cal outcomes. Although partial or complete recanalization was
achieved in a high proportion of subjects (74% in MELT and 66%
in PROACT II), the rate of complete recanalization was low (5%
in MELT, 18% in the treated arm of PROACT II; Saver, 2007).
COMBINED (INTRAVENOUS+ INTRA-ARTERIAL)
THROMBOLYSIS
This procedure should begin with the IV thrombolysis and should
proceed to IA therapy only if the ﬁrst intervention fails to accom-
plish revascularization. If the IA procedure also fails, the phar-
macological procedure may be complemented with a mechanical
thrombectomy.
The emergency management of stroke (EMS) trial compared
the efﬁcacy of combined (IV+ IA) thrombolysis with IA throm-
bolysis alone started within the ﬁrst 3 h of stroke (enrolled 35
patients). The results showed higher recanalization rates with
combined (IV+ IA) thrombolysis, but no difference between the
two groups in the clinical improvement. Hemorrhagic trans-
formation was seen more often if combined therapy was used
(Lewandowski et al., 1999).
In the interventionalmanagement of stroke (IMS) trial patients
with arterial occlusion, conﬁrmed by angiography, were treated
within the ﬁrst 3 h of stroke with 0.6mg/kg rt-PA IV. If needed, the
IV treatment was complemented with IA rt-PA (max. 22mg/2 h
directly into the thrombus) treatment. Results were compared to
primary results of placebo or IV rt-PA therapy from the NINDS
trial. The 3-month mortality in IMS subjects (16%) was lower
but not statistically different than the mortality of placebo (24%)
and rt-PA-treated subjects (21%) in the NINDS rt-PA stroke trial.
The rate of symptomatic intracerebral hemorrhage (6.3%) in IMS
subjects was similar to that of rt-PA-treated subjects (6.6%) but
higher than the rate in placebo-treated subjects (1.0%, p = 0.018).
The rates of intracerebral hemorrhage were similar in all groups
but IMS subjects had a signiﬁcantly better outcome at 3months
than NINDS placebo-treated subjects (IMS Study Investigators,
2004).
The IMS-II trial found combined thrombolysis (IV+ IA) to be
more beneﬁcial in acute stroke patients. Additional US therapy
was also used in this trial to dissolve the thrombus (IMS II Trial
Investigators, 2007; Tomsick et al., 2008). The trial involved rela-
tively few patients. Out of 73 IV (0.6mg/kg over 30min) treated
patients 50 received additional IA thrombolysis (max. 22mg IA)
and 34 underwent low energy US therapy as well. The mortality
rate was 16% and the rate of intracranial hemorrhage was 9.9%
in the IMS-II subjects. Patients undergoing combined thrombol-
ysis showed signiﬁcantly better outcome than the placebo group,
and better outcome than the rt-PA treated group of the NINDS
trial did.
MECHANICAL THROMBECTOMY
The IV thrombolysis does not always result in revasculariza-
tion and clinical improvement. The success rates of the IV rt-PA
treatment, based on anatomical location, are the following:
• Basilar artery: 30%
• Terminal part of the ICA: 6%
• M1 part of the MCA: 30%
• M2 part of the MCA: 44%
• Tandem ICA and MCA occlusion: 27% (Alexandrov, 2010b)
The failure of therapy can not solely be explained by the size of
the thrombus. The composition of the thrombus also plays a role,
because an arteriosclerotic plaque cannot be dissolved either by
rt-PA or by any other thrombolytic drug. Pharmacological throm-
bolysis is more effective in case of distal occlusions (e.g., small
branches of theMCA),whilemechanical devices aremore useful in
proximal main stem occlusions. The mechanical embolus removal
in cerebral ischemia (MERCI) technique and device removes the
embolus from the blood vessel, like a corkscrew.
Mechanical embolectomy can be beneﬁcial if:
• the patient is excluded from the pharmacological thrombolysis
(e.g., after surgery)
• pharmacological thrombolysis did not lead to recanalization
• the patient suffers from coagulopathy
• the thrombus is calciﬁed
• beyond the 3-h time window
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Disadvantages of MERCI:
• difﬁcult to reach the thrombus in sclerotic arteries
• dissection or perforation of the vessels can occur
• the thrombus might break into parts and cause distal occlusion
Mechanical embolus removal in cerebral ischemia was the ﬁrst
device approved by FDA in 2004. Since then more than 10,000
devices are in use worldwide, and many variants have been pro-
duced. The principle behind this intervention is that a MERCI
micro-catheter (thin metal spiral) goes through the thrombus, a
balloon is blown up distally from the thrombus and the device
removes the blood clot. The balloon is used for preventing distal
embolization (Alexandrov, 2010b).
In the MERCI-I trial 28 patients were treated with this tech-
nique. Sixty-four percent of the patients had successful recanal-
ization and nine (32%) out of the recanalized patients showed
signiﬁcant clinical improvement, reaching 0–2 points on the mod-
iﬁed Rankin Scale. In the MERCI-II trial partial or complete
recanalizationwas achieved in approximately half (48%)of the 141
treated patients. Clinically signiﬁcant procedural complications
occurred in 10 (7%) patients. Clinically symptomatic intracranial
bleeding occurred in 7.8% of the patients. Patients undergoing
successful recanalization showed signiﬁcantly better improvement
reaching 0–2 scores on the modiﬁed Rankin Scale at the 3-month
follow-up. The clinical improvement was 46% if recanalization
was successful and only 10% if recanalization failed (p = 0.001).
Mortality rates were better if recanalization was successful com-
pared to those when recanalization failed (32 vs. 54%; Smith et al.,
2008a).
Mechanical embolus removal in cerebral ischemia showed to
be particularly effective in case of main stem occlusions. Fifty-
three percent recanalization rate was achieved with MERCI for
internal carotid occlusions and 39% of these cases showed good
clinical outcome (reaching 0–2 scores on the modiﬁed Rankin
Scale). In the cases of internal carotid occlusion of those patients
who failed the MERCI revascularization procedure only 3% had
favorable outcome. Mortality rate was 30% in the group with suc-
cessful recanalization and73% in the ICAgroupwithout successful
recanalization.
In the Multi-MERCI trial if recanalization failed in response to
the IV rt-PA treatment mechanical thrombectomy was applied
(131 patients). Recanalization was successful in 75 of 131
(57.3%) cases. Additional methods (IA thrombolysis) increased
the recanalization rate to approximately 70%. Favorable clinical
outcomes (0–2 points at the modiﬁed Rankin Scale) occurred
in 36% and mortality was 34%; both outcomes were signiﬁ-
cantly related to vascular recanalization. Symptomatic intracere-
bral hemorrhage occurred in 16 patients (9.8%). Clinically signif-
icant procedural complications occurred in nine (5.5%) patients
(Flint et al., 2007; Smith et al., 2008a,b; Nogueira et al., 2009; Shi
et al., 2010).
The so-called Penumbra aspiration device was approved by
FDA in 2008. It consists of four micro-catheters, with different
sizes, according to the size of different arteries. Thedevice destructs
and aspirates the thrombus. Two trials have already proved the
effectiveness of the Penumbra device when used within the ﬁrst
8 h of acute stroke, in case of patients who score higher than eight
points on the NIHSS (Penumbra Pivotal Stroke Trial Investiga-
tors, 2009). The Penumbra device achieved recanalization in 80%
of the 125 patients and 25% of the patients had 0–2 points on
the modiﬁed Rankin Scale 3months after the procedure. The rate
of symptomatic intracerebral bleedings was 2% and the 3-month
mortality ratewas 30%.While the“corkscrew”devices, likeMERCI
go through the thrombus, most of the aspiration devices, like
Penumbra, are applied proximal to the thrombus; this decreases
the risk of embolization.
Many other devices have been developed so far. One of them is
the Catch Thromb-embolectomy System, which is a “basket-like”
4mm equipment. The Phenox blood clot remover acts like a brush
on a ﬂexible wire, containing brush-microﬁlaments. All these
attempts prove that there is no universal device able to remove
all types of thrombus. Furthermore, a successful recanalization
does not always automatically result in obvious clinical improve-
ment. However, the analysis of more than 1000 acute stroke cases
(33 trials) conﬁrmed that mechanical recanalization increases the
chance of good outcome.
Mechanical devices have several key advantages:
• recanalization occurs in approximately half of the treated
patients (conﬁrmed by angiography)
• recanalization occurs without the disruption of blood–brain
barrier
• no neurotoxicity (e.g., rt-PA is neurotoxic).
There are, however, some disadvantages to these techniques:
• they require an experienced interventional neuro-radiologist
• the devices are expensive
• they increase the risk of bleeding during the procedure.
Ongoing randomized trials (Khatri et al., 2008) are expected to
better deﬁne the role of these mechanical devices in the manage-
ment of acute ischemic stroke magnetic resonance and recanal-
ization of stroke clot using embolectomy (MR-RESCUE) and
IMS-III.
At this moment, pharmacological and mechanical stroke
treatment strategies are considered to be complementary.
STENTING IN ACUTE ISCHEMIC STROKE
There are only few studies investigating the utility of intracranial
stents for the treatment of acute ICA occlusion. An FDA trial,
including 20 patients reported the effectiveness and safety of this
procedure used in the ﬁrst 8 h of acute stroke. Recanalization was
successful in half of the patients. There was one symptomatic and
two asymptomatic intracranial hemorrhages. One month after the
procedure nine patients (45%) scored<1 and 60% of the patients
scored<3on themodiﬁedRankin Scale (Levy et al., 2009). In acute
stenting it is difﬁcult to pass through the atherosclerotic carotid
bifurcation. The concomitant antiplatelet therapy increases the
risk of hemorrhagic transformation or the risk of bleeding caused
by reperfusion. In a study of 25 patients 23 were successfully
recanalized. One bleeding and one carotid dissection occurred.
No data are available regarding the clinical outcomes (Jovin et al.,
2005).
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TRIALS COMBINING PHARMACOLOGICAL THROMBOLYSIS
WITH MECHANICAL RECANALIZATION DEVICES
The ongoing IMS-III trial is investigating whether a combined IV
and IA thrombolysis is superior to standard IV (standard dose of
0.9mg/kg) rt-PA therapy alone if it is initiatedwithin the ﬁrst 3 hof
acute stroke. The combined IV/IA group will receive a lower dose
of rt-PA (0.6mg/kg, 60mg max.) over 40min followed by imme-
diate angiography. If the thrombus is resolved, no additional IA
therapy is administered. If the occlusion is still present, the throm-
bolysis will be completed by IA treatment (max. dose of 22mg of
rt-PA). The IA treatment must be started within the ﬁrst 5 h and
must be completed within the end of the seventh hour of the acute
stroke. IA thrombolysis might be combined with low-intensity US
and thrombus-removal device as well. The clinical outcome is cal-
culated by themodiﬁed Rankin Scale 3months after the procedure
(Khatri et al., 2008).
The ongoing MR-RESCUE trial is evaluating the efﬁcacy of the
standard medical thrombolysis in case of proximal main branch
occlusion in the anterior circulation compared to the efﬁcacy of
mechanical thrombectomy (either with MERCI or Penumbra, in
the ﬁrst 8 h of acute stroke).
Those patients who arrive in the ﬁrst 4.5 h of stroke
might undergo standard IV thrombolysis before the mechanical
thrombectomy. The outcome is evaluated with modiﬁed Rankin
Scale 3months after stroke3.
The DAWN trial (DWI/PWI and CTP assessment in the
triage of wake-up and late presenting strokes undergoing neuro-
intervention) selects patients according to the MRI or CT perfu-
sion images more than 8 h after the onset of stroke. Patients with
witnessed or non-witnessed (includingwake-up) strokeswith“last
time seenwell”between 7 and23 h,having a large arterial occlusion
in the anterior circulation are selected. The treatment is initiated
between 8 and 24 h. Results will be evaluated by the modiﬁed
Rankin Scale 3months after stroke4.
IMPROVING PERFUSION BY MODULATING GLOBAL
REPERFUSION OR BY TRANS-ARTERIAL RETROGRADE
REPERFUSION TECHNIQUE
Theprinciple behind this strategy is to increase bloodﬂow through
the lepto-meningeal arteries or through the collaterals of the cir-
cle of Willis. This can be accomplished by pharmacological (IV
phenyl-epinephrine infusion) therapy or by a mechanical device.
The safety and efﬁcacy of neuroﬂo™ technology in ischemic stroke
(SENTIS) trial randomized subjects within the ﬁrst 14 h of acute
stroke. They tried to achieve beneﬁcial outcome by inserting an
intra-aortic balloon under the region of the renal arteries to
increase intracerebral blood ﬂow through the collaterals. The
results were compared to conventional medical therapy alone5.
Enrollment was completed in 2010, but only preliminary data
from 2008 are available at the moment: adverse events (fatal and
non-fatal) were found to appear equally (34%) in both the con-
trol and the treated groups. However, mortality was signiﬁcantly
3www.strokecenter.org/trials/TrialDetail.aspx?tid(559
4www.strokecenter.org/trials/TrialDetail.aspx?tid(960
5www.strokecenter.org/trials/TrialDetail.aspx?tid(618
lower for the treated population (6.4%) vs. the control population
(14.9%), with more stroke progression (8.5%) and hemorrhagic
transformation of the stroke area (4.3%) in the control population
(Uﬂacker et al., 2008).
NEUROPROTECTION
There are more than 100 medications that reached clinical phase
after they have been proven to be effective in animal models. None
of them has proved to be effective in human trials yet. Neuropro-
tectants would have the most clinical utility if they could be used
for both ischemic and hemorrhagic strokes early at the scene by
the paramedics (Danton and Dietrich, 2004).
“OPTIMAL” STROKE MANAGEMENT
The success of recanalization does not only depend on the efﬁcacy
of the thrombolysis or the mechanical thrombectomy but also on
the organization of the stroke units. All elements of the “chain of
stroke management”must be appropriately controlled in order to
increase the number of patients who are suitable for recanalization
therapy. The elements are the following: does the patient recog-
nize the symptoms of stroke? – Does the patient know about the
time window? – Do stroke patients have priority transport with
advanced notiﬁcation to the hospital? – Are pre- and in-hospital
pathways well organized? – Does the hospital have a stroke unit?
Why are stroke units special? International, multicenter, ran-
domized clinical trials have proven that treatment provided in
stroke units decreases the risk of death and severe disability by
minimum 25% (Stroke Unit Trialists’ Collaboration, 2000). The
Cochrane analyses conﬁrmed that patients treated in stroke units
(independent of age, gender, or stroke type) have a signiﬁcantly
better chance to be alive 1 year after the stroke and to live at home
instead of becoming severely disabled compared to patients who
FIGURE 2 | Patients who are alert and have a stable cardio-respiratory
status must be transferred to the CT directly. Unstable patients should
receive emergency therapy ﬁrst. If the thrombolysis cannot be done due to
the results of imaging or other criteria, the patient must be transferred to
the stroke unit. If thrombolysis is not contraindicated according to the
imaging, it must be started as soon as possible. All acute stroke patients
should be treated in stroke unit regardless whether they have already
received thrombolysis or not.
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FIGURE 3 |The future of acute stroke therapy. A neuroprotective drug is
administered on the site (not yet available).
werenot treated in such strokeunits. Themost important elements
of stroke units are (Alberts et al., 2005):
• experienced physicians, nurses, and physiotherapists, who are
familiar with stroke management
• monitoring for cardio-respiratory status
• protocolized stroke management
• integrated emergency system and well organized in-hospital
management
• laboratory and CT available around the clock
A personal “vision” about the future of stroke management:
• “Mobile CT” could differentiate ischemic strokes from hemor-
rhagic ones at the scene
• Neuroprotective agents (with proven effect both in ischemic
and hemorrhagic stroke) could be given by paramedics before
arrival to the stroke unit
• Alert patients with stable cardio-respiratory status should be
transferred directly to the CT. The neurological examination
and blood sampling should be performed at the radiology (CT)
area to save time (Figure 2)
• Within the 3 or 4.5-h time window thrombolysis should be
started IV in case of large vessel occlusion (both large vessel
and MCA branch), but the interventional team should also pre-
pare for the possible IA mechanical bridging therapy. Therefore,
if the IV procedure fails to result in clinical improvement, the
neurologist may individually decide on continuing the throm-
bolysis IA or on applying a mechanical removal device. All of
these methods might be combined (Figure 3)
• Patients both with IV or IA thrombolysis must be observed
at an intensive care unit for 72 h regardless of the success of
recanalization
• Rehabilitation must already be started at the stroke unit and
should be continued at the rehabilitation department/hospital.
SUMMARY
Successful acute stroke therapy can only be achieved by well
organized patient pathways. The success depends on the early
recognition of the alarming symptoms, on well/organized pre-
and in-hospital patient management, on the individual decisions
over the therapeutic modality, on the detailed monitoring in the
stroke units and on efﬁcient rehabilitation. Every componentmust
be well organized, because the strength of the chain is determined
by the weakest element.
REFERENCES
Adams, H. P. Jr., del Zoppo, G., Alberts,
M. J., Bhatt, D. L., Brass, L., Furlan,
A., Grubb, R. L., Higashida, R. T.,
Jauch, E. C., Kidwell, C., Lyden,
P. D., Morgenstern, L. B., Qureshi,
A. I., Rosenwasser, R. H., Scott, P.
A., Wijdicks, E. F., and American
Heart Association/American Stroke
Association Stroke Council, Amer-
ican Heart Association/American
Stroke Association Clinical Car-
diology Council, American Heart
Association/American Stroke Asso-
ciation Cardiovascular Radiology
and Intervention Council, Ather-
osclerotic Peripheral Vascular Dis-
ease Working Group, Quality of
Care Outcomes in Research Inter-
disciplinaryWorkingGroup. (2007).
Guidelines for the early manage-
ment of adults with ischemic stroke:
a guideline from the American
Heart Association/American Stroke
Association Stroke Council, Clin-
ical Cardiology Council, Cardio-
vascular Radiology and Interven-
tion Council, and the Atheroscle-
rotic Peripheral Vascular Disease
and Quality of Care Outcomes in
Research Interdisciplinary Working
Groups: the American Academy of
Neurology afﬁrms the value of this
guideline as an educational tool
for neurologists. Circulation 115,
e478–e534.
Alberts, M. J., Latchaw, R. E., Selman,
W. R., Shephard, T., Hadley, M. N.,
Brass, L. M., Koroshetz, W., Marler,
J. R., Booss, J., Zorowitz, R. D.,
Croft, J. B., Magnis, E., Mulligan,
D., Jagoda,A., O’Connor, R., Cawley,
C. M., Connors, J. J., Rose-DeRenzy,
J. A., Emr, M., Warren, M., and
Walker,M.D. (2005). Recommenda-
tions for comprehensive stroke cen-
ters: a consensus statement from the
Brain Attack Coalition. Stroke 36,
1597–1616.
Alexandrov, A. V. (2010a). Ultrasound
enhanced thrombolysis for stroke. J.
Int. Med. 267, 209–219.
Alexandrov, A. V. (2010b). Current and
future recanalisation strategies for
acute ischemic stroke (Review). J.
Intern. Med. 267, 209–219.
Astrup, J., Siesjö, B. K., and Symon,
L. (1981). Thresholds in cerebral
ischemia – the ischemic penumbra.
Stroke 12, 723–725.
Cornu, C., Amsallem, E., and Serradj-
Jaillard, A. A. (2001). Throm-
bolytic therapy for acute ischemic
stroke. Am. J. Cardiovasc. Drugs 4,
281–292.
Csiba, L., Paschen, W., and Hoss-
mann, K. A. (1983). A topo-
graphic quantitative method for
measuring brain tissue pH under
physiological and pathophysiolog-
ical conditions. Brain Res. 289,
334–337.
Csiba, L., Paschen, W., and Mies,
G. (1985). Regional changes in
tissue pH and glucose content
during cortical spreading depres-
sion in rat brain. Brain Res. 336,
167–170.
Danton, G. H., and Dietrich, W. D.
(2004). The search for neuroprotec-
tive strategies in stroke. AJNR Am. J.
Neuroradiol. 25, 181–194.
Davis, S. M., Donnan, G. A., Parsons,
M. W., Levi, C., Butcher, K. S.,
Peeters, A., Barber, P. A., Bladin,
C., De Silva, D. A., Byrnes, G.,
Chalk, J. B., Fink, J. N., Kimber, T.
E., Schultz, D., Hand, P. J., Frayne,
J., Hankey, G., Muir, K., Gerraty,
R., Tress, B. M., Desmond, P. M.,
and EPITHET investigators. (2008).
Effects of alteplase beyond 3 h after
stroke in the echoplanar imaging
thrombolytic evaluation trial (EPI-
THET): a placebo-controlled ran-
domised trial. Lancet Neurol. 7,
299–309.
del Zoppo,G. J.,Higashida,R. T.,Furlan,
A. J., Pessin, M. S., Rowley, H. A.,
and Gent, M. (1998). PROACT: a
phase II randomized trial of recom-
binant pro-urokinase by direct arte-
rial delivery in acute middle cere-
bral artery stroke. PROACT inves-
tigators. Prolyse in acute cere-
bral thromboembolism. Stroke 29,
4–11.
Flint, A. C., Duckwiler, G. R., Budzik,
R. F., Liebeskind, D. S., Smith, W. S.,
and MERCI and Multi MERCIWrit-
ing Committee. (2007). Mechani-
cal thrombectomy of intracranial
internal carotid occlusion: pooled
results of the MERCI and multi
MERCI part I trials. Stroke 38,
1274–1280.
www.frontiersin.org May 2011 | Volume 2 | Article 32 | 9
Frendl and Csiba Acute treatment of ischemic stroke
Furlan, A., Higashida, R., Wechsler, L.,
Gent, M., Rowley, H., Kase, C.,
Pessin, M., Ahuja, A., Callahan, F.,
Clark, W. M., Silver, F., and Rivera,
F. (1999). Intra-arterial prouroki-
nase for acute ischemic stroke. The
PROACT II study: a randomized
controlled trial. Prolyse in acute
cerebral thromboembolism. JAMA
282, 2003–2011.
Furlan, A. J., and Abou-Chebl, A.
(2002). The role of recombi-
nant pro-urokinase (r-pro-UK) and
intra-arterial thrombolysis in acute
ischaemic stroke: the PROACT tri-
als. Prolyse in acute cerebral throm-
boembolism. Curr. Med. Res. Opin.
18(Suppl. 2), s44–s47.
Hacke, W., Albers, G., Al-Rawi, Y.,
Bogousslavsky, J., Davalos, A.,
Eliasziw, M., Fischer, M., Furlan, A.,
Kaste, M., Lees, K. R., Soehngen,
M., Warach, S., and DIAS Study
Group. (2005). The desmoteplase in
acute ischemic stroke trial (DIAS): a
phase II MRI-based 9-hour window
acute stroke thrombolysis trial with
intravenous desmoteplase. Stroke
36, 66–73.
Haley, E. C. Jr., Lyden, P. D., John-
ston, K. C., Hemmen, T. M., and
TNK in Stroke Investigators. (2005).
A pilot dose-escalation safety study
of tenecteplase in acute ischemic
stroke. Stroke 36, 607–612.
IMS Study Investigators. (2004). Com-
bined intravenous and intra-arterial
recanalisation for acute ischemic
stroke: the Interventional Manage-
ment of Stroke Study. Stroke 35,
904–911.
IMS II Trial Investigators. (2007).
The Interventional Management of
Stroke (IMS) II Study. Stroke 38,
2127–2135.
Jovin, T. G., Gupta, R., Uchino, K., Jun-
greis, C. A., Wechsler, L. R., Ham-
mer, M. D., Tayal, A., and Horowitz,
M. B. (2005). Emergent stenting of
extracranial internal carotid artery
occlusion in acute stroke has a
high revascularization rate. Stroke
36, 2426–2430.
Kakuda, W., Lansberg, M. G., Thijs, V.
N., Kemp, S. M., Bammer, R., Wech-
sler, L. R., Moseley, M. E., Marks, M.
P.,Albers,G.W., and DEFUSE Inves-
tigators. (2008). Optimal deﬁnition
for PWI/DWI mismatch in acute
ischemic stroke patients. J. Cereb.
Blood Flow Metab. 28, 887–891.
Khatri, P., Hill, M. D., Palesch, Y. Y.,
Spilker, J., Jauch, E. C., Carrozzella,
J. A., Demchuk, A. M., Martin, R.,
Mauldin, P., Dillon, C., Ryckborst,
K. J., Janis, S., Tomsick, T. A., Brod-
erick, J. P., and Interventional Man-
agement of Stroke III Investigators.
(2008). Methodology of the Inter-
ventional Management of Stroke III
Trial. Int. J. Stroke 3, 130–137.
Kuroiwa, T., Miyasaka, N., Fengyo, Z.,
Yamada, I., Nakane, M., Nagaoka, T.,
Tamura, A., Ohno, K. (2007). Exper-
imental ischemic brain edema: mor-
phological and magnetic resonance
imaging ﬁndings. Neurosurg. Focus
22, E11.
Kwiatkowski, T. G., Libman, R. B.,
Frankel, M., Tilley, B. C., Morgen-
stern, L. B., Lu, M., Broderick, J. P.,
Lewandowski, C. A., Marler, J. R.,
Levine, S. R., and Brott, T. (1999).
Effects of tissue plasminogen activa-
tor for acute ischemic stroke at one
year. National Institute of Neurolog-
ical Disorders and Stroke Recombi-
nant Tissue Plasminogen Activator
Stroke Study Group. N. Engl. J. Med.
340, 1781–1787.
Levy, E. I., Siddiqui, A. H., Crumlish, A.,
Snyder, K. V., Hauck, E. F., Fiorella,
D. J., Hopkins, L. N., and Mocco,
J. (2009). First Food and Drug
Administration-approved prospec-
tive trial of primary intracra-
nial stenting for acute stroke:
SARIS (stent-assisted recanalization
in acute ischemic stroke). Stroke 40,
3552–3556.
Lewandowski, C. A., Frankel, M., Tom-
sick, T. A., Broderick, J., Frey, J.,
Clark, W., Starkman, S., Grotta, J.,
Spilker, J., Khoury, J., and Brott, T.
(1999). Combined intravenous and
intra-arterial r-TPA versus intra-
arterial therapy of acute ischemic
stroke: emergency management of
stroke (EMS) bridging trial. Stroke
30, 2598–2605.
Liebeskind, D. S. (2009). Reversing
stroke in the 2010s: lessons from
desmoteplase in acute ischemic
stroke-2 (DIAS-2). Stroke 40,
3156–3158.
Marler, J. R., Tilley, B. C., and Lu, M.,
Brott, T. G., Lyden, P. C., Grotta,
J. C., Broderick, J. P., Levine, S.
R., Frankel, M. P., Horowitz, S. H.,
Haley, E. C. Jr., Lewandowski, C.
A., and Kwiatkowski, T. P. (2000).
Early stroke treatment associated
with better outcome: the NINDS
rt-PA stroke study. Neurology 55,
1649–1655.
Micieli, G., Marcheselli, S., and Tosi,
P. (2009). Safety and efﬁcacy of
alteplase in the treatment of acute
ischemic stroke. Vasc. Health Risk
Manag. 5, 397–409.
Molina, C. A., Grotta, J. C., Garami,
Z., Ford, S. R., Alvarez-Sabin, J.,
Montaner, J., Saqqur, M., Dem-
chuk, A. M., Moyé, L. A., Hill,
M. D., Wojner, A. W., CLOT-
BUST Investigators. (2004).
Ultrasound-enhanced systemic
thrombolysis for acute ischemic
stroke. N. Engl. J. Med. 351,
2170–2178.
Molina, C. A., Ribo, M., Rubiera,
M., Montaner, J., Santamarina, E.,
Delgado-Mederos, R., Arenillas, J.
F., Huertas, R., Purroy, F., Delgado,
P., and Alvarez-Sabín, J. (2006).
Microbubble administration accel-
erates clot lysis during continuous
2-MHz ultrasound monitoring in
stroke patients treated with intra-
venous tissue plasminogen activator.
Stroke 37, 425–429.
Murray, V., Norrving, B., Sandercock,
P. A. G., Terént, A., Wardlaw, J. M.,
andWester, P. (2010). The molecular
basis of thrombolysis and its clinical
application in stroke. J. Intern. Med.
267, 191–208.
Nogueira, R. G., Liebeskind,D. S., Sung,
G., Duckwiler, G., and Smith, W.
S. (2009). MERCI; Multi MERCI
Writing Committee. Predictors of
good clinical outcomes, mortality,
and successful revascularization in
patients with acute ischemic stroke
undergoing thrombectomy: pooled
analysis of the mechanical embo-
lus removal in cerebral ischemia
(MERCI) and Multi MERCI Trials.
Stroke 40, 3777–3783.
Ogawa, A., Mori, E., Minematsu, K.,
Taki, W., Takahashi, A., Nemoto,
S., Miyamoto, S., Sasaki, M., Inoue,
T., and MELT Japan Study Group.
(2007). Randomized trial of intraar-
terial infusion of urokinase within
6 hours of middle cerebral artery
stroke: the middle cerebral artery
embolism local ﬁbrinolytic inter-
vention trial (MELT) Japan. Stroke
38, 2633–2639.
Olivot, J. M., Mlynash, M., Thijs, V. N.,
Purushotham, A., Kemp, S., Lans-
berg, M. G., Wechsler, L., Gold, G.
E., Bammer, R., Marks, M. P., and
Albers, G. W. (2009). Geography,
structure, and evolution of diffusion
and perfusion lesions in diffusion
and perfusion imaging evaluation
for understanding stroke evolution
(DEFUSE). Stroke 40, 3245–3251.
Paciaroni, M., Medeiros, E.,
and Bogousslavsky, J. (2009).
Desmoteplase. Expert Opin. Biol.
Ther. 9, 773–778.
Parsons, M. W., Miteff, F., Bateman,
G. A., Spratt, N., Loiselle, A.,
Attia, J., and Levi, C. R. (2009).
Acute ischemic stroke: imaging-
guided tenecteplase treatment in an
extended time window. Neurology
72, 915–921.
Penumbra Pivotal Stroke Trial Inves-
tigators. (2009). The penumbra
pivotal stroke trial: safety and
effectiveness of a new generation of
mechanical devices for clot removal
in intracranial large vessel occlusive
disease. Stroke 40, 2761–2768.
Qureshi, A. I., Harris-Lane, P., Kir-
mani, J. F., Janjua, N., Divani, A.
A., Mohammad, Y. M., Suarez, J.
I., and Montgomery, M. O. (2006).
Intra-arterial reteplase and intra-
venous abciximab in patients with
acute ischemic stroke: an open-label,
dose-ranging, phase I study. Neu-
rosurgery 59, 789–796; discussion
796–797.
Qureshi, A. I., Pande, R. U., Kim, S.
H., Hanel, R. A., Kirmani, J. F., and
Yahia, A. M. (2002). Third gener-
ation thrombolytics for the treat-
ment of ischemic stroke. Curr. Opin.
Investig. Drugs 3, 1729–1732.
Saver, J. F. (2006). Time is brain!-
quantiﬁed. Stroke 37, 263–266.
Saver, J. L. (2004). Number needed to
treat estimates incorporating effects
over the entire range of clinical out-
comes: novel derivation method and
application to thrombolytic therapy
for acute stroke. Arch. Neurol. 61,
1066–1067.
Saver, J. L. (2007). Intra-arterial ﬁb-
rinolysis for acute ischemic stroke:
the message of MELT. Stroke 38,
2627–2628.
Saver, J. L.,Gornbein, J.,Grotta, J.,Liebe-
skind, D., Lutsep, H., Schwamm, L.,
Scott, P., and Starkman, S. (2009).
Number needed to treat to beneﬁt
and to harm for intravenous tissue
plasminogen activator therapy in the
3- to 4.5-hour window: joint out-
come table analysis of the ECASS 3
trial. Stroke 40, 2433–2437.
Saver, J. L., Smith, E. E., Fonarow, G.
C., Reeves, M. J., Zhao, X., Olson, D.
M., Schwamm, L. H., and on behalf
of the GWTG-Stroke Steering Com-
mittee. (2010). The “golden hour”
and acute brain ischemia: presenting
features and lytic therapy in>30,000
patients arriving within 60 minutes
of stroke onset stroke. Stroke 41,
1431–1439.
Segura, T., Calleja, S., and Jordan, J.
(2008). Recommendations and
treatment strategies for the man-
agement of acute ischemic stroke.
Expert Opin. Pharmacother. 9,
1071–1085.
Shi, Z. S., Loh, Y., Walker, G., and
Duckwiler, G. R. (2010). Clinical
outcomes in middle cerebral artery
trunk occlusions versus secondary
division occlusions after mechani-
cal thrombectomy: pooled analysis
of the mechanical embolus removal
in cerebral ischemia (MERCI) and
multi MERCI trials. Stroke 41,
953–960.
Frontiers in Neurology | Stroke May 2011 | Volume 2 | Article 32 | 10
Frendl and Csiba Acute treatment of ischemic stroke
Smith, W. S., Sung, G., Starkman, S.,
Saver, J. L., Kidwell, C. S., Gobin,
Y. P., Lutsep, H. L., Nesbit, G. M.,
Grobelny, T., Rymer, M. M., Silver-
man, I. E., Higashida, R. T., Budzik,
R. F., Marks, M. P., and MERCI
Trial Investigators. (2008a). Safety
and efﬁcacy of mechanical embolec-
tomy in acute stroke: results of the
MERCI trial. Stroke 39, 1205–1212.
Smith, W. S., Sung, G., Saver, J., Budzik,
R., Duckwiler, G., Liebeskind, D.
S., Lutsep, H. L., Rymer, M. M.,
Higashida, R. T., Starkman, S.,
Gobin,Y. P.,Multi MERCI Investiga-
tors, Frei, D., Grobelny, T., Hellinger,
F.,Huddle,D.,Kidwell,C.,Koroshetz,
W., Marks, M., Nesbit, G., and Sil-
verman, I. E. (2008b). Mechanical
thrombectomy for acute ischemic
stroke: ﬁnal results of the multi
MERCI trial. Stroke 39, 1205–1212.
Stroke Unit Trialists’ Collaboration.
(2007). Organised inpatient (stroke
unit) care for stroke. Cochrane Data-
base Syst. Rev. CD000197.
The National Institute of Neurolog-
ical Disorders and Stroke rt-PA
Stroke Study Group. (1995). Tis-
sue plasminogen activator for acute
ischemic stroke. N. Engl. J. Med. 333,
1581–1587.
Tomsick, T., Broderick, J., Carrozella,
J., Khatri, P., Hill, M., Palesch,
Y., Khoury, J., and Interventional
Management of Stroke II Investi-
gators. (2008). Revascularization
results in the Interventional
Management of Stroke II trial.
AJNR Am. J. Neuroradiol. 29,
582–587.
Uﬂacker, R., Schönholz, C., Papamiti-
sakis, N., and SENTIS trial. (2008).
Interim report of the SENTIS trial:
cerebral perfusion augmentation via
partial aortic occlusion in acute
ischemic stroke. J. Cardiovasc. Surg.
(Torino) 49, 715–721.
Wardlaw, J. M., Murray, V., Berge,
E., and Del Zoppo, G. J. (2009).
Thrombolysis for acute ischaemic
stroke. Cochrane Database Syst. Rev.
CD000213.
Wintermark, M., Albers, G. W., Alexan-
drov, A. V., Alger, J. R., Bammer,
R., Baron, J. C., Davis, S., Demaer-
schalk, B. M., Derdeyn, C. P., Don-
nan, G. A., Eastwood, J. D., Fiebach,
J. B., Fisher, M., Furie, K. L., Gold-
makher, G. V., Hacke, W., Kidwell,
C. S., Kloska, S. P., Köhrmann, M.,
Koroshetz, W., Lee, T. Y., Lees, K.
R., Lev, M. H., Liebeskind, D. S.,
Ostergaard,L.,Powers,W. J., Proven-
zale, J., Schellinger, P., Silbergleit, R.,
Sorensen, A. G., Wardlaw, J., Wu, O.,
and Warach, S. (2008). Acute stroke
imaging research roadmap. Stroke
39, 1621–1628.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 10 February 2011; accepted:
09 May 2011; published online: 27 May
2011.
Citation: Frendl A and Csiba L
(2011) Pharmacological and non-
pharmacological recanalization strategies
in acute ischemic stroke. Front. Neur.
2:32. doi: 10.3389/fneur.2011.00032
This article was submitted to Frontiers
in Stroke, a specialty of Frontiers in
Neurology.
Copyright © 2011 Frendl and Csiba. This
is an open-access article subject to a non-
exclusive license between the authors and
Frontiers Media SA, which permits use,
distribution and reproduction in other
forums, provided the original authors and
source are credited and other Frontiers
conditions are complied with.
www.frontiersin.org May 2011 | Volume 2 | Article 32 | 11
